Landmark Surgery May Pave Way For Legalising Broader Organ Exchange Model
In a groundbreaking medical feat, two men in Tamil Nadu's Coimbatore have been given a new lease of life after undergoing India's first inter-hospital liver swap transplant - a move that required a special court order to override current rules limiting swaps to within a single hospital.
The two patients, admitted at GEM Hospital and Sri Ramakrishna Hospital, were both suffering from end-stage liver disease and had family donors - their wives - who were unfortunately incompatible.
However, doctors discovered that the donors were a match for the other patient, opening the door to a rare, life-saving exchange.
"Under current Indian transplant laws, organ swaps are only permitted within the same hospital," Dr Anand Vijay, transplant surgeon at GEM Hospital, said. "But we felt this exchange could save both lives, so we coordinated with Sri Ramakrishna Hospital and obtained court permission to proceed."
Following due legal process and approval from the government transplant committee, which independently verified donor consent and ruled out any commercial interest, the surgeries were successfully conducted.
A special "green corridor" was created in Coimbatore to ensure swift transport of the harvested livers between hospitals.
"This model expands the donor pool tremendously for patients who have willing but incompatible family donors," said Dr Magnus Jayaraj, also from GEM Hospital. "It could be a game-changer for liver and kidney transplants."
Doctors rule out this paving way for organ trade. Dr R Jayapal from Sri Ramakrishna Hospital added: "No shortcuts were taken. These transplants underwent all legal protocols. This is life-saving, not a loophole for organ trade. The government committee would meet, investigate and confirm the relationship of donors with documentary evidence and only the transplant is permitted."
The procedures, which cost Rs 20 lakh each, were entirely covered under the Tamil Nadu Chief Minister's Health Insurance Scheme, ensuring zero cost for the families. Both patients are recovering well post-surgery.
Tamil Nadu has long led the way in organ donation in India, a country where the donation rate still remains low. Experts now hope this successful inter-hospital liver swap could lead to broader legalisation and protocol development for similar life-saving initiatives in the future.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
7 minutes ago
- The Hindu
Simpler tests could slash biosimilar costs, widen patient access
Most of the drugs that we consume are called 'small molecule drugs'. Their chemical structure is reasonably simple. Disprin, for instance, has a molecular weight of around 180 daltons. There is another breed of drugs that are very large, complex molecules. For instance, the molecular weight of insulin is around 5,800 daltons and that of the monoclonal antibody remicade, about 150,000 daltons. (One dalton is equal to one-12th the mass of a carbon-12 atom.) Small molecule drugs also tend to have fixed structures that do not change for the duration of their use. In contrast, the complex molecules, which we call biologics, are produced in biological systems and therefore during their production slight variations in the structure may arise. However, these variations may have no impact on the stability of the molecule, its efficacy or its side effects. When a company produces a small molecule drug for the first time, it seeks patent protection for that drug. That is, no competitor may make that drug for several years. It is only when the drug goes 'off patent' that competitors may make it. In the absence of competition, the originator company can price the drug very high. Once there is competition, the competitor companies produce generics, which are copies of the original drug. They don't undertake the research and development to make the drug and they may not spend as much on marketing and sales, so the costs of generics are also much lower. Most of the drugs that you and I take are generics and are priced very cheaply compared to the originator drug. A good example is Sovaldi, a drug used to treat hepatitis C: it originally cost $84,000 for a 12-week course in the US but that dropped to $1,000 once Indian generic firms started making it. Largely it is generic drugs that keep us in India alive and well. Since biologics made by a generic firm will be produced by different biological systems, they may not be identical to those made by the originator company. Thus they are called biosimilars, not generics. For many years, a debate has raged over how much proof is required for a manufacturer to prove that a given biosimilar will work as well as the original biologic drug. Therefore, whereas much simpler testing was required to show that a generic small molecule was working like the originator molecule, there are more elaborate and expensive tests for biosimilars. Major drug regulators such as those of the US, the UK, and in Europe have been working to determine how they can simplify the requirements for approving a biosimilar, in view of the availability of modern analytical techniques. For example, the UK has removed animal trials and the US has planned to replace them with more human-relevant methods (like using organoids). In India, this requirement has not yet been updated although there is a proposal to waive animal studies on a case-by-case basis. Some have also argued that India should follow the practices of the UK and the US. The same holds for the more expensive clinical trials, which in the UK are currently required only in certain cases. Biosimilars need to be made less expensively while ensuring efficacy and minimal adverse effects. The larger the number of affordable biosimilars, the more options we will have for our patients. Gayatri Saberwal is a consultant at the Tata Institute for Genetics and Society.
Time of India
2 hours ago
- Time of India
Plan for purifiers in Nehru Park dropped by govt following survey
New Delhi: Delhi govt has decided to drop the plan for installing 150 air purifiers in Nehru Park after the majority of walkers and joggers opposed it during a recently conducted two-day survey. Environment minister Manjinder Singh Sirsa earlier announced plans to set up 150 outdoor air purifiers at Nehru Park, where breathable air is available to people the entire year, especially during the peak winter season. After analysing the results of the survey, Sirsa said, "We will not install the air purifiers now as the majority of people responded that they want only trees in the park. We committed that we will go ahead with this project only if more than 80% of people were in favour." Delhi Pollution Control Committee (DPCC) conducted a two-day survey in July to take the feedback of walkers and joggers at Nehru Park. During the survey, the public was asked to fill out a form with a question: "Would you like to have an air purifier in your park?" The question included four responses: "Yes, any day", "Yes, when low maintenance and low cost", "No", and "I only want trees." You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi Out of 221 responses received, 84 people (38.01%) said they want only trees. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like She Was Everyone's Dream Girl In 90's, This Is Her Now The Latest Article Undo An additional 29 walkers (13.12%) opted for the "no" option. Thirty-three people (14.95%) said they want an air purifier only when there is low maintenance and low cost. However, 75 people (33.93%) were in favour of air purifiers. Even experts opposed the plan. Green activist Bhavreen Kandhari earlier said, "The Rs 25 crore smog towers at CP and Anand Vihar were deemed ineffective, with DPCC confirming they reduced PM2.5 levels by just 17% within a limited 100m radius, while costing Rs 15 lakh per month to operate. Scaling such technology across the city would cost over Rs 11 lakh crore again, a huge misuse of public funds. Worse, this new project is being trialled in Nehru Park, one of the city's few green lungs, where air quality is already better than surrounding zones," said Kandhari. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
Time of India
3 hours ago
- Time of India
10 fire engines take 3 hours to douse blaze that hits 67-year-old unit of Bengal's legacy med co
1 2 Kolkata: A fire broke out at a Dey's Medical factory on Bondel Road around 4 pm on Saturday, sending thick black smoke billowing across the neighbourhood and forcing residents of nearby buildings to evacuate. While nobody was injured in the fire, three firemen fell ill after inhaling toxic fumes while working inside the affected building. The factory was closed at the time but the blaze at its pharmaceutical unit sparked widespread panic, with residents rushing out of their homes and traffic coming to a standstill in the area. Ten fire engines took nearly three hours to control the blaze. The billowing smoke was so dense that it was visible from as far as Park Circus, a few motorists said. The exact cause of the fire was yet to be ascertained. You Can Also Check: Kolkata AQI | Weather in Kolkata | Bank Holidays in Kolkata | Public Holidays in Kolkata "The fire broke out in the pharmaceutical unit of the factory. Barring the guards, there was nobody inside the factory as Saturday is a holiday. As no work was on, a short circuit could have caused the fire, but the reason can be confirmed only after a forensic inspection," said a fire department officer, supervising the rescue operation. "The pocket where the fire started had some packaging chemicals. It spread fast," said one of the firefighters on the scene. Sources said the Dey family, which owned the business, had recently invested Rs 40 crore to upgrade the manufacturing facility to conform to the World Health Organization's Good Manufacturing Practices (GMP). "The manufacturing facility was upgraded in the past one-and-a-half years. We are praying and hoping the fire did not cause much damage to the facility as 70% of our drugs are manufactured at this unit," said company director Rishav Dey. The factory will resume operations only after the investigation is completed. "At first, we thought it was just someone burning waste, but the smoke quickly turned dense and dark," said Namita Chowdhury, a resident of 43, Bondel Road, located right opposite the factory. "There was a lot of shouting and confusion. People were coming out on balconies and calling their neighbours." Chowdhury said six members of the family, including two children, were inside the house when the incident took place. No one was injured, though all suffered a bout of coughing amid the smoke. The blaze caused major traffic disruptions on Syed Amir Ali Avenue, Rifle Range Road, Palm Avenue and the Bondel Gate flyover, as fire engines and emergency personnel cordoned off the area. Picnic Garden resident Fahim Ansari, who was stuck in the jam on Rifle Range Road, described the moment he realised something was seriously wrong. "As I rode towards the Bondel Gate flyover, the entire area looked like it was under a dark cloud. The Dey's Medical factory on Bondel Road was inaugurated in 1958 by then former chief minister Bidhan Chandra Roy. Though Dey's Medical has multiple manufacturing facilities now, the Bondel Gate factory is the only one, where pharmaceutical products, including tablets, syrups and eye drops, are manufactured. The other unit makes cosmetic products, including body and hair oil. There are also some factories outside the state to which it contracts medicine manufacturing. Dey's Medical founder Bhupendranath Dey forayed into the pharmaceutical business in 1941, when he rented a space on Lindsay Street opposite New Market to establish Dey's Medical Stores. Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
